- Progression free survival at the 9-month follow-up is tracking
in line with previously published data
- Immune activation is further validated in the ONCOS-102
treated group
- First line mesothelioma remains the focus for next phase of
development
OSLO, Norway, May 4, 2020 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors, today
releases an update from the randomized phase I/II trial of
ONCOS-102 in combination with standard of care chemotherapy in
malignant pleural mesothelioma.
The trial is an open label, randomized, exploratory phase I/II
trial adding ONCOS-102 to standard of care (SoC) chemotherapy
(pemetrexed/cisplatin) in first and second (and later) line
mesothelioma to assess safety, immune activation and clinical
efficacy. In total, 31 patients have been enrolled with 20 patients
in the experimental group receiving the ONCOS-102 and SoC, and 11
patients in a control group receiving SoC only. The first set of
data was reported in January 2020,
see link to press release here.
All patients have now completed the 9-month follow-up. The
median Progression Free Survival (mPFS) remains in line with
previously published data and compares favorably with historical
control. The first line patients continue to perform well, and will
be the population prioritized for future development. The updated
PFS data are being complemented by biomarker analyses and early
data demonstrate enhanced immune activation and modulation of tumor
microenvironment in ONCOS-102-treated patients compared to the
control group. 12-months clinical data as well as more extensive
immune activation and biomarker data will be released in the middle
of 2020.
Dr. Magnus Jäderberg, Chief Medical Officer of Targovax,
said: "We are very pleased to see the encouraging early PFS
figures holding up in the 9-month analysis. The data look
particularly promising for first line patients, and the
preparations for a subsequent checkpoint inhibitor combination
trial in this population with a big pharma collaboration partner
are progressing according to plan."
For further information, please contact:
Renate Birkeli
Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas
Tinglum
Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-releases-update-for-mesothelioma-trial-combining-oncos-102-and-chemotherapy,c3102786